Overview

A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction

Status:
Terminated
Trial end date:
2016-01-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with recurrent or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the stomach or gastroesophageal junction.
Phase:
Phase 2
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.